Letter | Published:

Haloperidol-induced presynaptic dopamine supersensitivity is blocked by chronic lithium


SUPERSENSITIVITY following the interruption of synaptic transmission within the dopamine (DA) system has now been established by behavioural1–3, biochemical4–6 and electrophysiological7,8 evidence. Following production of lesions which interupt DA input1, or treatment with pharmacological agents which chronically disrupt dopaminergic transmission3,9,10, an increase in the sensitivity of postsynaptic (receiving input from dopaminergic neurones) responses of cells to DA and DA agonists has been observed. However, several studies have suggested that in vivo, presynaptic DA or ‘autoreceptors’ (that is, dopaminoceptive sites on DA-containing cells) may have an important physiological role in the modulation of DA synthesis and release11–13. Thus, alterations in the sensitivity of presynaptic cells may have profound effects on the availability of the neurotransmitter. To date, only one study has attempted to investigate whether dopaminergic supersensitivity could be a presynaptic, as well as a postsynaptic, phenomenon; following long-term treatment of rats with a phenothiazine, an increase in the sensitivity of DA-containing neurones in the substantia nigra to the DA agonist, apomorphine, has been observed14. We present here electrophysiological evidence for increased presynaptic sensitivity following chronic haloperidol treatment, as measured by both the direct iontophoretic application of DA and the systemic administration of apomorphine to DA-containing cells in the zona compacta region of the substantia nigra. In addition, it has been found recently that rats treated concurrently with lithium and haloperidol fail to develop postsynaptic supersensitivity, as measured by alterations in behavioural sensitivity15,16 and DA-receptor binding16. Several groups have theorised that alterations in catecholamine receptor sensitivity may be a factor in the aetiology of affective disorders, especially manic-depressive illness17,18. As lithium therapy has been shown to be effective in preventing recurrent episodes of mania and depression in manic-depressive illness19, it is of interest to determine whether, at the level of individual DA neurones in the CNS, chronic lithium treatment could also affect the development of presynaptic supersensitivity. We provide here electrophysiological evidence for the blockade of presynaptic supersensitivity development following chronic lithium treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Ungerstedt, U. Acta physiol. scand. suppl. 367, 1–122 (1971).

  2. 2

    Klawans, H. L. & Rubovitz, H. J. neurol. Transm. 33, 235 (1974).

  3. 3

    Tarsy, D. & Baldessarini, R. J. Neuropharmacology 13, 927–940 (1974).

  4. 4

    Gianutsos, G., Hynes, M. D. & Lal, H. Biochem. Pharmac. 24, 581–582 (1975).

  5. 5

    Gianutsos, G. & Moore, K. Life Sci. 20, 1585–1592 (1977).

  6. 6

    Burt, D., Creese, I. & Snyder, S. H. Science 196, 326–328 (1977).

  7. 7

    Siggins, G. R., Hoffer, B. J. & Ungerstedt, U. Life Sci. 15, 779–792 (1974).

  8. 8

    Yarbrough, G. Eur. J. Pharmac. 31, 367–369 (1975).

  9. 9

    Sayers, A. C., Bürki, H. R., Ruch, W. & Asper, H. Psychopharmacologia 41, 97–104 (1975).

  10. 10

    Christensen, A. V., Fjalland, B. & Møller-Nielsen, I. Psychopharmacologia 48, 1–6 (1976).

  11. 11

    Iversen, L., Rogawski, M. & Miller, R. Molec. Pharmac. 12, 251–263 (1976).

  12. 12

    Walters, J. & Roth, R. Naunyn-Schmiedebergs Arch. exp. Path. Pharmac. 296, 5–14 (1976).

  13. 13

    Westfall, T., Besson, M-J., Giorguieff, M-F. & Glowinski, J. Naunyn-Schmiedebergs Arch. exp. Path. Pharmac. 292, 279–287 (1976).

  14. 14

    Nowycky, M. & Roth, R. Naunyn-Schmiedebergs Arch. Pharmac. 300, 247–254 (1977).

  15. 15

    Klawans, H. L., Weiner, W. J. & Nausieda, P. A. Prog. Neuropsychopharmac. 1, 53–60 (1977).

  16. 16

    Pert, A., Rosenblatt, J., Sivit, C., Pert, C. B. & Bunney, W. E. Jr, Science (in the press).

  17. 17

    Ashcroft, G. W. et al. Lancet ii, 573–577 (1972).

  18. 18

    Bunney, W. E., Jr, Post, R. M., Andersen, A. E. & Kopanda, R. T. Commun. Psychopharmac. 1, 393–406 (1977).

  19. 19

    Schou, M. Neurosci. Res. Prog. Bull. 14, 117–131 (1976).

  20. 20

    Thomsen, K. Acta pharmac. Tox. 33, 92–102 (1973).

  21. 21

    Bunney, B. S., Aghajanian, G. K. & Roth, R. H. Nature 245, 123–125 (1973).

  22. 22

    Segal, M. Nature 250, 70–73 (1974).

  23. 23

    Trendelenburg, U. Pharmac. Rev. 15, 225–276 (1963).

  24. 24

    Bunney, B. S., Walters, J., Roth, R. & Aghajanian, G. J. Pharmac. exp. Ther. 185, 560–571 (1973).

  25. 25

    Glowinski, J. in Biology of the Major Psychoses (ed. Freedman, D.) 233–276 (Raven, New York, 1975).

  26. 26

    Haigler, H. & Aghajanian, G. J. Pharmac. exp. Ther. 188, 688–699 (1974).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.